Table 1.
Summary of clinical variables for training and validation sets
| Variable | Training N (%) | Validation N (%) | p-value |
|---|---|---|---|
| Number of (donor, recipient) pairs | 733 | 522 | |
| Disease at transplant | 0.07 | ||
| AML | 451 (62) | 347 (66) | |
| ALL | 282 (38) | 175 (34) | |
| Recipient sex | 0.99 | ||
| Male | 386 (53) | 275 (53) | |
| Female | 347 (47) | 247 (47) | |
| Donor sex | 0.02 | ||
| Male | 475 (65) | 371 (71) | |
| Female | 258 (35) | 151 (29) | |
| Karnofsky score | 0.63 | ||
| 10–80 | 164 (22) | 126 (24) | |
| 90–100 | 509 (69) | 359 (69) | |
| Unknown | 60 ( 8) | 37 ( 7) | |
| Recipient age at transplant | 0.38 | ||
| 0–9 years | 62 ( 8) | 46 ( 9) | |
| 10–19 years | 109 (15) | 56 (11) | |
| 20–29 years | 135 (18) | 92 (18) | |
| 30–39 years | 112 (15) | 83 (16) | |
| 50–59 years | 134 (18) | 98 (19) | |
| 60 years and older | 28 ( 4) | 18 ( 3) | |
| Median (range) | 35 (1–67) | 38 (0–68) | |
| Donor age at donation | 0.90 | ||
| 10–19 years old | 16 ( 2) | 11 ( 2) | |
| 20–29 years old | 268 (37) | 194 (37) | |
| 30–39 years old | 253 (35) | 183 (35) | |
| 40–49 years old | 158 (22) | 102 (20) | |
| 50 years and older | 38 ( 5) | 32 ( 6) | |
| Median (range) | 33 (19–60) | 33 (18–61) | |
| Year of transplant | <0.001 | ||
| 2000 | 29 ( 4) | 25 ( 5) | |
| 2001 | 23 ( 3) | 27 ( 5) | |
| 2002 | 33 ( 5) | 35 ( 7) | |
| 2003 | 45 ( 6) | 40 ( 8) | |
| 2004 | 78 (11) | 45 ( 9) | |
| 2005 | 119 (16) | 61 (12) | |
| 2006 | 135 (18) | 72 (14) | |
| 2007 | 135 (18) | 71 (14) | |
| 2008 | 129 (18) | 54 (10) | |
| 2009 | 7 ( 1) | 72 (14) | |
| 2010 | 0 ( 0) | 20 ( 4) | |
| Campath given | 0.86 | ||
| Yes | 20 ( 3) | 13 ( 2) | |
| No | 708 (97) | 504 (97) | |
| Unknown | 5 ( 1) | 5 ( 1) | |
| ATG given | 0.85 | ||
| Yes | 147 (20) | 107 (20) | |
| No | 586 (80) | 415 (80) | |
| Graft type | 0.16 | ||
| PBSC | 423 (58) | 322 (62) | |
| BM | 310 (42) | 200 (38) | |
| Disease status | 0.003 | ||
| Early | 413 (56) | 337 (65) | |
| Intermediate | 320 (44) | 185 (35) | |
| Conditioning | 0.43 | ||
| TBI | 434 (60) | 298 (58) | |
| No TBI | 292 (40) | 220 (42) | |
| Donor race / ethnicity | 0.17 | ||
| Caucasian, non-Hispanic | 621 (85) | 458 (88) | |
| African-American, non-Hispanic | 7 (1) | 11 (2) | |
| Asian, non-Hispanic | 12 (2) | 6 (1) | |
| Native American, non-Hispanic | 9 ( 1) | 9 (2) | |
| Hispanic, Caucasian | 12 ( 2) | 8 (2) | |
| Hispanic, race unknown | 25 ( 3) | 11 (2) | |
| Other or unknown | 47 ( 6) | 19 (4) | |
| Recipient race / ethnicity | 0.66 | ||
| Caucasian, non-Hispanic | 639 (87) | 464 (89) | |
| African-American, non-Hispanic | 10 ( 1) | 11 (2) | |
| Asian, non-Hispanic | 12 ( 2) | 4 (1) | |
| Native American, non-Hispanic | 1 (<1) | 2 (<1) | |
| Hispanic, Caucasian | 43 (6) | 25 (5) | |
| Hispanic, race unknown | 4 ( 1) | 1 (<1) | |
| Other or unknown | 24 ( 3) | 15 ( 3) | |
| Donor T/S Ratio | 0.49 | ||
| Unknown | 2 (<1) | 0 (<1) | |
| 1.0–1.1 | 154 (21) | 135 (26) | |
| 1.1–1.2 | 98 (13) | 83 (16) | |
| 1.2–1.3 | 69 ( 9) | 44 ( 8) | |
| 1.3–1.4 | 44 ( 6) | 26 ( 5) | |
| 1.4–1.5 | 28 ( 4) | 15 ( 3) | |
| 1.5–2 | 30 ( 4) | 24 ( 5) | |
| >2 | 4 ( 1) | 3 (10) | |
| Donor height | 0.07 | ||
| Unknown | 88 (12) | 82 (16) | |
| 100–160 | 36 (5) | 23 ( 4) | |
| 160–170 | 147 (20) | 88 (17) | |
| 170–180 | 222 (30) | 150 (29) | |
| 180–190 | 192 (26) | 153 (29) | |
| >190 | 48 (7) | 20 ( 4) | |
| Donor weight | <0.001 | ||
| Unknown | 2 (<1) | 82 (16) | |
| 25–50 | 10 (1) | 2 (<1) | |
| 50–60 | 59 (8) | 26 ( 5) | |
| 60–70 | 97 (13) | 52 (10) | |
| 70–80 | 140 (19) | 93 (18) | |
| 80–90 | 150 (20) | 111 (21) | |
| 90–100 | 142 (19) | 0 (<1) | |
| >100 | 133 (18) | 70 (13) | |
| Recipient ABO blood type | 0.82 | ||
| Unknown | 8 (1) | 3 ( 1) | |
| A Rh+ | 253 (35) | 174 (33) | |
| B Rh+ | 72 (10) | 46 ( 9) | |
| AB Rh+ | 23 (3) | 14 ( 3) | |
| O Rh+ | 267 (36) | 204 (39) | |
| A Rh− | 42 (6) | 28 ( 5) | |
| B Rh− | 14 (2) | 7 ( 1) | |
| AB Rh− | 7 (1) | 3 ( 1) | |
| O Rh− | 47 ( 6) | 42 (8) | |
| GvHD prophylaxis | 0.32 | ||
| Tacrolimus+MMF+others | 70 (10) | 68 (13) | |
| Tacrolimus+MTX+others ex. MMF | 386 (53) | 270 (52) | |
| Tacrolimus+others ex. MTX, MMF | 32 ( 4) | 17 ( 3) | |
| Tacrolimus alone | 17 ( 2) | 6 ( 1) | |
| CSA+MMF+others | 15 ( 2) | 12 ( 2) | |
| CSA+MTX+others ex. Tacrolimus, | 191 (26) | 132 (25) | |
| MMF | |||
| CSA+others ex. Tacrolimus, MTX, | 8 ( 1) | 8 ( 2) | |
| MMF | |||
| CSA alone | 11 ( 2) | 8 ( 2) | |
| other | 3 (<1) | 0 (<1) |